ArticleIranian journal of cancer prevention2015

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran.

Nahid Hatam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.